RESUMEN

AIMS: Previous studies have demonstrated the therapeutic potential for human embryonic stem cell-derived neural precursor cells (hES-NPCs) in autoimmune and genetic animal models of demyelinating diseases. Herein, we tested whether intravenous (i.v.) administration of hES-NPCs would impact central nervous system (CNS) demyelination in a cuprizone model of demyelination. METHODS: C57Bl/6 mice were fed cuprizone (0.2%) for 2 weeks and then separated into two groups that either received an i.v. injection of hES-NPCs or i.v. administration of media without these cells. After an additional 2 weeks of dietary cuprizone treatment, CNS tissues were analysed for detection of transplanted cells and differences in myelination in the region of the corpus callosum (CC). RESULTS: Cuprizone-induced demyelination in the CC was significantly reduced in mice treated with hES-NPCs compared with cuprizone-treated controls that did not receive stem cells. hES-NPCs were identified within the brain tissues of treated mice and revealed migration of transplanted cells into the CNS. A limited number of human cells were found to express the mature oligodendrocyte marker, O1, or the astrocyte marker, glial fibrillary acidic protein. Reduced apoptosis and attenuated microglial and astrocytic responses were also observed in the CC of hES-NPC-treated mice. CONCLUSIONS: These findings indicated that systemically administered hES-NPCs migrated from circulation into a demyelinated lesion within the CNS and effectively reduced demyelination. Observed reductions in astrocyte and microglial responses, and the benefit of hES-NPC treatment in this model of myelin injury was not obviously accountable to tissue replacement by exogenously administered cells.

Asunto(s)

Cuerpo Calloso/patología , Cuprizona/farmacología , Enfermedades Desmielinizantes/terapia , Vaina de Mielina/patología , Células-Madre Neurales , Oligodendroglía/patología , Animales , Astrocitos/efectos de los fármacos , Astrocitos/metabolismo , Astrocitos/patología , Diferenciación Celular , Cuerpo Calloso/efectos de los fármacos , Cuerpo Calloso/metabolismo , Enfermedades Desmielinizantes/inducido químicamente , Enfermedades Desmielinizantes/metabolismo , Enfermedades Desmielinizantes/patología , Humanos , Ratones , Vaina de Mielina/efectos de los fármacos , Vaina de Mielina/metabolismo , Oligodendroglía/efectos de los fármacos , Oligodendroglía/metabolismo

RESUMEN

The neurotoxin 6-hydroxydopamine has been widely used to model aspects of Parkinson's disease in rodents, but the mechanisms underlying toxin-induced dopaminergic degeneration and functional impairment have not been fully elucidated. The main aim of the present study was to assess a possible role for calpains in neurochemical and behavioral deficits following unilateral infusion of intrastriatal 6-hydroxydopamine in adult rats. Toxin administration produced a profound dopaminergic denervation, as indicated by a 90-95% reduction in dopamine transporter radiolabeling measured in the caudate-putamen at 2 weeks post-lesion. Treatment with 6-hydroxydopamine also resulted in calpain activation in both caudate-putamen and substantia nigra, as measured by the appearance of calpain-specific spectrin breakdown products. Calpain activation peaked at 24 h after 6-hydroxydopamine infusion and remained elevated at later time points. In contrast, caspase-3-mediated spectrin cleavage subsided within 48 h in both brain areas. In a subsequent experiment, calpain inhibition was achieved by intrastriatal infusion of an adenovirus expressing the endogenous calpain inhibitor, calpastatin. Calpastatin delivery abolished the lesion-induced calpain-mediated spectrin cleavage and alleviated forelimb asymmetries resulting from unilateral intrastriatal 6-hydroxydopamine. Unexpectedly, dopamine transporter and tyrosine hydroxylase labeling revealed significant neuroprotection, not in the nigrostriatal pathway but rather in the ventral tegmental area. These findings support a role for calpain activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. However, after near-total dopaminergic depletion, the primary benefit of calpain inhibition may not occur within the nigrostriatal dopaminergic pathway itself.

Asunto(s)

Adrenérgicos/administración & dosificación , Calpaína/metabolismo , Cuerpo Estriado/efectos de los fármacos , Dopamina/metabolismo , Actividad Motora/efectos de los fármacos , Oxidopamina/administración & dosificación , Animales , Autorradiografía , Proteínas de Unión al Calcio/farmacología , Calpaína/antagonistas & inhibidores , Caspasa 3/metabolismo , Cocaína/análogos & derivados , Cocaína/metabolismo , Cuerpo Estriado/metabolismo , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Lateralidad Funcional/efectos de los fármacos , Proteínas Fluorescentes Verdes/genética , Masculino , Desempeño Psicomotor/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Espectrina/metabolismo , Factores de Tiempo , Tirosina 3-Monooxigenasa/metabolismo

RESUMEN

A failure of autoreactive T cells to undergo apoptosis may contribute to the pathogenesis of multiple sclerosis (MS). The role of the inhibitor of apoptosis (IAP) family of anti-apoptotic proteins such as X-linked IAP (XIAP), human inhibitor of apoptosis-1 (HIAP-1), human inhibitor of apoptosis-2 (HIAP-2), neuronal apoptosis inhibitory protein (NAIP) and Survivin in relapsing-remitting, secondary-progressive, primary-progressive or benign forms of MS is unclear. We report here that expression of the IAP family of genes in peripheral blood samples and brain tissues from MS cases support a role for differential regulation of these potent anti-apoptotic proteins in the pathology of MS. XIAP mRNA and protein levels were elevated in peripheral blood mononuclear cells from patients with active disease relative to normal subjects. In patients with active MS, HIAP-1 and HIAP-2 mRNA levels were elevated in resting T cells while NAIP mRNA was increased in whole blood. In post-mortem MS brain tissue, XIAP and HIAP-1 in myelin lesions were co-localized with microglia and T cells, respectively. Only in primary-progressive patients was Survivin expression elevated suggestive of a distinct pathological basis for this subtype of MS. Taken together, these results suggest that patterns of inhibitor of apoptosis expression in immune cells may have value in distinguishing between MS subtypes and offer insight into the mechanisms responsible for their distinct clinical courses.

Asunto(s)

Proteínas Inhibidoras de la Apoptosis/genética , Proteínas Inhibidoras de la Apoptosis/inmunología , Esclerosis Múltiple/genética , Esclerosis Múltiple/inmunología , Adulto , Anciano , Autoinmunidad/genética , Autoinmunidad/inmunología , Proteína 3 que Contiene Repeticiones IAP de Baculovirus , Western Blotting , Encéfalo/patología , Encéfalo/fisiología , Enfermedades Desmielinizantes/genética , Enfermedades Desmielinizantes/inmunología , Enfermedades Desmielinizantes/patología , Femenino , Expresión Génica/inmunología , Perfilación de la Expresión Génica , Humanos , Factores Inmunológicos/genética , Factores Inmunológicos/inmunología , Proteínas Inhibidoras de la Apoptosis/metabolismo , Masculino , Microglía/inmunología , Proteínas Asociadas a Microtúbulos/genética , Proteínas Asociadas a Microtúbulos/inmunología , Proteínas Asociadas a Microtúbulos/metabolismo , Persona de Mediana Edad , Esclerosis Múltiple/patología , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/inmunología , Proteínas de Neoplasias/metabolismo , Proteína Inhibidora de la Apoptosis Neuronal/genética , Proteína Inhibidora de la Apoptosis Neuronal/inmunología , Proteína Inhibidora de la Apoptosis Neuronal/metabolismo , Survivin , Linfocitos T/inmunología , Linfocitos T/metabolismo , Ubiquitina-Proteína Ligasas , Proteína Inhibidora de la Apoptosis Ligada a X/genética , Proteína Inhibidora de la Apoptosis Ligada a X/inmunología , Proteína Inhibidora de la Apoptosis Ligada a X/metabolismo

RESUMEN

X-linked IAP protein is a potent inhibitor of cell death. Here, we describe a novel transgenic mouse in which the human XIAP gene is expressed under the control of the neuron-specific enolase promoter (NSE-xiap). We demonstrate that nigrostriatal dopamine neurons of NSE-xiap mice were resistant to the damaging effects of the dopaminergic neurotoxin MPTP. MPTP-induced reduction of striatal dopamine metabolism was also attenuated in NSE-xiap mice. Furthermore, NSE-xiap mice treated with MPTP did not exhibit deficits in exploratory behaviour in an open-field test. Taken together, these findings suggest that strategies to enhance neuronal expression of XIAP may provide therapeutic benefit for the treatment of neurodegeneration in Parkinson's disease.

Asunto(s)

Muerte Celular/genética , Resistencia a Medicamentos/genética , Neuronas/metabolismo , Trastornos Parkinsonianos/metabolismo , Proteínas/metabolismo , Sustancia Negra/metabolismo , 1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina/farmacología , Animales , Conducta Animal/efectos de los fármacos , Conducta Animal/fisiología , Muerte Celular/efectos de los fármacos , Dopamina/metabolismo , Conducta Exploratoria/efectos de los fármacos , Conducta Exploratoria/fisiología , Inmunohistoquímica , Ratones , Ratones Transgénicos , Neostriado/efectos de los fármacos , Neostriado/metabolismo , Neostriado/patología , Vías Nerviosas/efectos de los fármacos , Vías Nerviosas/metabolismo , Vías Nerviosas/patología , Neuronas/efectos de los fármacos , Trastornos Parkinsonianos/genética , Trastornos Parkinsonianos/terapia , Fosfopiruvato Hidratasa/genética , Regiones Promotoras Genéticas/genética , Proteínas/genética , Sustancia Negra/efectos de los fármacos , Sustancia Negra/patología , Proteína Inhibidora de la Apoptosis Ligada a X

RESUMEN

The inhibitor of apoptosis protein family members inhibit cell death resulting from a variety of apoptotic stimuli. However, the endogenous expression of neuronal inhibitor of apoptosis proteins following axonal injury has not been thoroughly examined. Neonatal facial motoneurons are highly susceptible to axotomy-induced apoptosis, whereas adult facial motoneurons survive axotomy. We hypothesized that the endogenous expression of inhibitor of apoptosis proteins may be involved in the differential susceptibility of adult and neonatal facial motoneurons to axonal injury. In this study, we examined the expression of two endogenous inhibitor of apoptosis proteins, neuronal apoptosis inhibitory protein and x-linked inhibitory apoptosis protein, in adult and neonatal rat facial motoneurons following axotomy. Analyses using reverse-transcription polymerase chain reaction and in situ hybridization indicated that neuronal apoptosis inhibitory protein mRNA was increased in neonatal facial nuclei 24 h post axotomy. In the adult, neuronal apoptosis inhibitory protein mRNA expression increased at 1, 3, 7 and 14 days post axotomy, while little change in the expression of X-linked inhibitory apoptosis protein mRNA was detected at any age or time point time point analyzed. Interestingly, immunohistochemistry using antibodies for neuronal apoptosis inhibitory protein and X-linked inhibitory apoptosis protein, revealed the level of these proteins was higher in the neonatal motoneurons when compared with the adult. Furthermore, immunohistochemistry and western blot for neuronal apoptosis inhibitory protein revealed, in contrast to the observed increase in neuronal apoptosis inhibitory protein mRNA, a decline in the expression of neuronal apoptosis inhibitory protein following axotomy in the adult, whereas no change in neuronal apoptosis inhibitory protein was detected in neonatal facial motoneurons. X-linked inhibitory apoptosis protein, as analyzed by immunohistochemistry and western blot, remained unchanged by axotomy in neonatal motoneurons and adult motoneurons. These results indicate differential expression and/or turnover of inhibitor of apoptosis proteins in neonatal versus adult facial motoneurons, and suggest the level of inhibitor of apoptosis protein expression alone is not an indicator of cell fate following axotomy.

Asunto(s)

Apoptosis/fisiología , Traumatismos del Nervio Facial/metabolismo , Neuronas Motoras/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Proteínas/metabolismo , Animales , Animales Recién Nacidos , Axotomía/métodos , Western Blotting/métodos , Traumatismos del Nervio Facial/patología , Lateralidad Funcional , Inmunohistoquímica/métodos , Etiquetado Corte-Fin in Situ , Masculino , Neuronas Motoras/patología , Proteína Inhibidora de la Apoptosis Neuronal , ARN Mensajero/metabolismo , Ratas , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Factores de Tiempo , Proteína Inhibidora de la Apoptosis Ligada a X

RESUMEN

Expression of the transcription factor c-Jun is induced in neurons of the central nervous system (CNS) in response to injury. Mechanical transection of the nigrostriatal pathway at the medial forebrain bundle (MFB) results in the delayed retrograde degeneration of the dopamine neurons in the substantia nigra pars compacta (SNc) and induces protracted expression and phosphorylation of c-Jun. However, the role of c-Jun after axotomy of CNS neurons is unclear. Here, we show that adenovirus-mediated expression of a dominant negative form of c-Jun (Ad.c-JunDN) inhibited axotomy-induced dopamine neuron death and attenuated phosphorylation of c-Jun in nigral neurons. Ad.c-JunDN also delayed the degeneration of dopaminergic nigral axons in the striatum after MFB axotomy. Taken together, these findings suggest that activation of c-Jun mediates the loss of dopamine neurons after axotomy injury.

Asunto(s)

Apoptosis/fisiología , Axotomía , Dopamina/fisiología , Proteínas Proto-Oncogénicas c-jun/fisiología , Animales , Supervivencia Celular/fisiología , Cromatografía Líquida de Alta Presión , Inmunohistoquímica , Masculino , Fosforilación , Proteínas Proto-Oncogénicas c-jun/química , Proteínas Proto-Oncogénicas c-jun/metabolismo , Ratas , Ratas Wistar , Serina/metabolismo

RESUMEN

Parkinson's disease (PD) is a progressive neurodegenerative disorder of the basal ganglia, associated with the inappropriate death of dopaminergic neurons of the substantia nigra pars compacta (SNc). Here, we show that adenovirally mediated expression of neuronal apoptosis inhibitor protein (NAIP) ameliorates the loss of nigrostriatal function following intrastriatal 6-OHDA administration by attenuating the death of dopamine neurons and dopaminergic fibres in the striatum. In addition, we also addressed the role of the cysteine protease caspase-3 activity in this adult 6-OHDA model, because a role for caspases has been implicated in the loss of dopamine neurons in PD, and because NAIP is also a reputed inhibitor of caspase-3. Although caspase-3-like proteolysis was induced in the SNc dopamine neurons of juvenile rats lesioned with 6-OHDA and in adult rats following axotomy of the medial forebrain bundle, caspase-3 is not induced in the dopamine neurons of adult 6-OHDA-lesioned animals. Taken together, these results suggest that therapeutic strategies based on NAIP may have potential value for the treatment of PD.

Asunto(s)

Dopamina/metabolismo , Neostriado/metabolismo , Degeneración Nerviosa/tratamiento farmacológico , Proteínas del Tejido Nervioso/genética , Vías Nerviosas/metabolismo , Trastornos Parkinsonianos/tratamiento farmacológico , Sustancia Negra/metabolismo , Anfetamina/farmacología , Precursor de Proteína beta-Amiloide/efectos de los fármacos , Precursor de Proteína beta-Amiloide/metabolismo , Animales , Anticuerpos/farmacología , Caspasa 3 , Caspasas/efectos de los fármacos , Caspasas/metabolismo , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Fragmentación del ADN/efectos de los fármacos , Fragmentación del ADN/fisiología , Modelos Animales de Enfermedad , Colorantes Fluorescentes/farmacología , Vectores Genéticos/fisiología , Inmunohistoquímica , Masculino , Trastornos del Movimiento/tratamiento farmacológico , Trastornos del Movimiento/etiología , Trastornos del Movimiento/fisiopatología , Neostriado/patología , Neostriado/fisiopatología , Degeneración Nerviosa/metabolismo , Degeneración Nerviosa/fisiopatología , Vías Nerviosas/patología , Vías Nerviosas/fisiopatología , Proteína Inhibidora de la Apoptosis Neuronal , Neurotoxinas/farmacología , Oxidopamina/farmacología , Trastornos Parkinsonianos/metabolismo , Trastornos Parkinsonianos/fisiopatología , Ratas , Ratas Wistar , Sustancia Negra/patología , Sustancia Negra/fisiopatología , Simpaticolíticos/farmacología

RESUMEN

Accumulating evidence strongly suggests that apoptosis contributes to neuronal cell death in a variety of neurodegenerative contexts. Activation of the cysteine protease caspase-3 appears to be a key event in the execution of apoptosis in the central nervous system (CNS). As a result, mice null for caspase-3 display considerable neuronal expansion usually resulting in death by the second week of life. At present, 14 caspase family members have been identified and subdivided into three subgroups on the basis of preference for specific tetrapeptide motifs using a positional scanning combinatorial substrate library. Caspase-3 is a group II member (2, 3, 7) categorized by an absolute substrate requirement for aspartic acid in the P4 position of the scissile bond. The preferred cleavage motif (DExD) for group II caspases is found in many structural, metabolic and repair proteins essential for cellular homeostasis. Consistent with the proposal that apoptosis plays a central in role human neurodegenerative disease, caspase-3 activation has recently been observed in stroke, spinal cord trauma, head injury and Alzheimer's disease. Indeed, peptide-based caspase inhibitors prevent neuronal loss in animal models of head injury and stroke suggesting that these compounds may be the forerunners of non-peptide small molecules that halt apoptosis processes implicated in these neurodegenerative disorders. A clear link between an hereditary neurodegenerative disorder and failed caspase inhibition has recently been proposed for spinal muscular atrophy (SMA). In severe SMA, the neuronal specific inhibitor of apoptosis (IAP) family member known as NAIP is often dysfunctional due to missense and truncation mutations. IAPs such as NAIP potently block the enzymatic activity of group II caspases (3 and 7) suggesting that NAIP mutations may permit unopposed developmental apoptosis to occur in sensory and motor systems resulting in lethal muscular atrophy. Conversely, adenovirally-mediated overexpression of NAIP or the X-linked IAP called XIAP reduces the loss of CA1 hippocampal neurons following transient forebrain ischemia. Taken together, these findings suggest that anti-apoptotic strategies may some day have utility in the treatment of neurodegenerative disease. The present review will summarize some of the recent evidence suggesting that apoptosis inhibitors may become a practical therapeutic approach for both acute and chronic neurodegenerative conditions.

Asunto(s)

Apoptosis/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Animales , Apoptosis/fisiología , Isquemia Encefálica/enzimología , Isquemia Encefálica/fisiopatología , Caspasa 3 , Caspasas/química , Caspasas/metabolismo , Activación Enzimática/fisiología , Humanos , Familia de Multigenes/fisiología , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/farmacología , Enfermedades Neurodegenerativas/tratamiento farmacológico

RESUMEN

Transient forebrain ischemia produced by four-vessel occlusion (4-VO) triggers the delayed death of CA1 neurons in the hippocampus, resulting in behavioral deficits of spatial learning performance. We demonstrate that CA1 neuronal loss induced by 4-VO (12 min) is preceded by a selective and marked elevation of catalytically active caspase-3 in these neurons, indicative of apoptosis. Virally mediated overexpression of the anti-apoptotic gene X chromosome-linked inhibitor of apoptosis protein (XIAP) prevented both the production of catalytically active caspase-3 and degeneration of CA1 neurons after transient forebrain ischemia. CA1 neurons protected in this manner appeared to function normally, as assessed by immunohistochemical detection of the neuronal activity marker nerve growth factor inducible-A and by spatial learning performance in the Morris water maze. These findings indicate that caspase-3 activation is a key event in ischemic neuronal death and that blockade of this event by XIAP overexpression permits CA1 neurons to survive and operate properly after an ischemic insult.

Asunto(s)

Apoptosis/genética , Hipocampo/citología , Ataque Isquémico Transitorio/fisiopatología , Proteínas del Tejido Nervioso/genética , Cromosoma X , Animales , Conducta Animal/fisiología , Química Encefálica/genética , Caspasa 3 , Caspasas/metabolismo , Fragmentación del ADN , Regulación Enzimológica de la Expresión Génica/fisiología , Hipocampo/irrigación sanguínea , Hipocampo/química , Masculino , Aprendizaje por Laberinto/fisiología , Proteína Inhibidora de la Apoptosis Neuronal , Neuronas/química , Neuronas/citología , Neuronas/enzimología , Proteínas/genética , Ratas , Ratas Wistar , Proteína Inhibidora de la Apoptosis Ligada a X

RESUMEN

Administration of dopamine receptor agonists to rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway produce changes in the denervated striatum that enable a subsequent injection to elicit more vigorous circling. The molecular basis for this behavioural phenomenon, termed priming, is unknown. D1-receptor-related priming has been associated with a profound elevation of immediate-early gene (IEG) expression in the denervated striatum. Since immediate-early genes encode known transcriptional regulating factors, this observation has led to the suggestion that IEG induction may play a role in the gene signaling pathways which mediate priming. In the present study, we addressed the role of induction of the IEG fosB in dopamine agonist-induced priming by examining whether inhibition of the synthesis of FosB proteins (FosB and DeltaFosB) by intrastriatal delivery of an antisense oligonucleotide to fosB reduced apomorphine-induced priming. Intrastriatal delivery of an antisense, but not a random, oligonucleotide to fosB 18 and 6 h before apomorphine reduced the ability of this mixed D1¿D2-like receptor agonist to prime circling induced by the specific D1-like receptor agonist SKF 38393. Immunohistochemical analysis revealed that only the antisense oligonucleotide blocked apomorphine-induced increases in FosB-like immunoreactivity in the denervated striatum. In contrast, apomorphine-induced increases in JunB-, NGFI-A- and Fos2-16-like immunoreactivities were unaffected by either the antisense or random oligonucleotides, indicating that the antisense oligonucleotide attenuated apomorphine-induced priming by selectively blocking the synthesis of FosB proteins. Taken together, these findings suggest that fosB induction in the denervated striatum plays a role in mediating D1-receptor-related priming. Dopamine replacement therapy for Parkinson's disease is often complicated by the development of dyskinetic side effects. Results from the present study suggest that D1-receptor-mediated increases in fosB expression may be involved in those intracellular events responsible for the generation of these debilitating side effects.

Asunto(s)

2,3,4,5-Tetrahidro-7,8-dihidroxi-1-fenil-1H-3-benzazepina/farmacología , Cuerpo Estriado/fisiología , Regulación de la Expresión Génica , Genes Inmediatos-Precoces , Proteínas Inmediatas-Precoces , Actividad Motora/fisiología , Oligonucleótidos Antisentido/farmacología , Proteínas Proto-Oncogénicas c-fos/biosíntesis , Receptores de Dopamina D1/fisiología , Animales , Apomorfina/farmacología , Cuerpo Estriado/efectos de los fármacos , Proteínas de Unión al ADN/biosíntesis , Proteína 1 de la Respuesta de Crecimiento Precoz , Regulación de la Expresión Génica/efectos de los fármacos , Genes Inmediatos-Precoces/efectos de los fármacos , Masculino , Actividad Motora/efectos de los fármacos , Oxidopamina , Proteínas Proto-Oncogénicas c-jun/biosíntesis , Ratas , Ratas Wistar , Receptores de Dopamina D1/efectos de los fármacos , Conducta Estereotipada/efectos de los fármacos , Factores de Transcripción/biosíntesis , Transcripción Genética

RESUMEN

We show here that transient forebrain ischemia selectively elevates levels of neuronal apoptosis inhibitory protein (NAIP) in rat neurons that are resistant to the injurious effects of this treatment. This observation suggests that increasing NAIP levels may confer protection against ischemic cell death. Consistent with this proposal, we demonstrate that two other treatments that increase neuronal NAIP levels, systemic administration of the bacterial alkaloid K252a and intracerebral injection of an adenovirus vector capable of overexpressing NAIP in vivo, reduce ischemic damage in the rat hippocampus. Taken together, these findings suggest that NAIP may play a key role in conferring resistance to ischemic damage and that treatments that elevate neuronal levels of this antiapoptotic protein may have utility in the treatment of stroke.

Asunto(s)

Hipocampo/lesiones , Hipocampo/metabolismo , Ataque Isquémico Transitorio/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Adenoviridae/genética , Animales , Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Carbazoles/administración & dosificación , Carbazoles/uso terapéutico , Expresión Génica/efectos de los fármacos , Terapia Genética , Vectores Genéticos , Hipocampo/irrigación sanguínea , Alcaloides Indólicos , Ataque Isquémico Transitorio/patología , Ataque Isquémico Transitorio/terapia , Masculino , Factores de Crecimiento Nervioso/administración & dosificación , Factores de Crecimiento Nervioso/uso terapéutico , Proteínas del Tejido Nervioso/genética , Proteína Inhibidora de la Apoptosis Neuronal , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Neuronas/patología , Ratas , Ratas Wistar